| Document and Entity Information | 12 Months Ended |
| Dec. 31, 2022 | |
| Cover [Abstract] | |
| Document Type | DEFA14A |
| Amendment Flag | true |
| Amendment Description | This proxy statement supplement (the “Supplement”) supplements and amends the definitive proxy statement on Schedule 14A (the “Proxy Statement”) filed with the Securities and Exchange Commission by agilon health, inc. (the “Company”) on April 14, 2023. Following the filing of the Proxy Statement, we determined that due to administrative error (i) while the stock option grant date fair values of stock options granted to our named executive officers (“NEOs”) in the 2022 fiscal year were accurately reflected in the table entitled “Grants of Plan-Based Awards for Fiscal Year 2022”, the Summary Compensation Table included in the Executive Compensation section of the Proxy Statement inadvertently overstated the grant date fair values of stock options granted to our NEOs in the 2022 fiscal year, and as a result, information for the 2022 fiscal year in the “CEO Pay Ratio” and “Pay Versus Performance” section of the Proxy Statement that is based on the Summary Compensation Table was overstated; and (ii) the Proxy Statement contained other administrative errors. This Supplement is being filed to correct these errors by (1) reproducing the Summary Compensation Table, originally set forth on page 49 of the Proxy Statement, with changes for Fiscal Year 2022 to the columns designated “Option Awards”, “All Other Compensation” and “Total”, (2) as a result of the changes to the Summary Compensation Table, (a) reducing the ratio of our CEO’s pay to our median employee’s total compensation, as originally set forth on page 62 of the Proxy Statement, to reflect the lower amount of the CEO’s total compensation as updated in the Summary Compensation Table included in this Supplement and (b) reproducing the table included in the “Pay Versus Performance” section of the Proxy Statement, originally set forth on pages 63 through 65 of the Proxy Statement, to reflect the lower amounts of the NEOs’ total compensation as updated in the Summary Compensation Table included in this Supplement. In addition, to correct certain other administrative errors, this Supplement (x) reproduces the table shown under the heading “Accelerated Vesting of Equity on a Change in Control” in the Executive Compensation section of the Proxy Statement, originally set forth on page 59 of the Proxy Statement, with changes to the columns “Value of RSUs” and “Value of PSUs”, and (y) amends the table included in the “Security Ownership of Certain Beneficial Owners and Management” section of the Proxy Statement, originally set forth on page 70 of the Proxy Statement. This corrected information is provided below and replaces the information originally included in the Proxy Statement in its entirety. |
| Entity Registrant Name | agilon health, inc. |
| Entity Central Index Key | 0001831097 |
| Pay vs Performance Disclosure - USD ($) | 12 Months Ended | |
| Dec. 31, 2022 | Dec. 31, 2021 | |
| Pay vs Performance Disclosure [Table] | ||
| Pay vs Performance [Table Text Block] | Pay Versus Performance Statemen Year Summary Compensation Table Total for PEO (1) Compensation Actually Paid to PEO (2)(3) Average Summary Compensation Table Total for Non-PEO NEOs (4) Average Compensation Actually Paid to Non-PEO NEOs (3)(5) Value of Initial Fixed $100 Investment Based On: Net Income (thousands) (7) Adjusted EBITDA (thousands) (8) Total Shareholder Return Peer Group Total Shareholder Return (6) 2022 $5,789,157 ($ 30,811,711) $1,961,158 ($ 1,410,451) $ 70.17 $ 118.00 ($106,864) $ 4,251 2021 $1,256,250 $79,887,250 $4,001,770 $26,200,762 $117.39 $120.35 ($406,787) ($38,619) (1) Amounts reported in this column are the amounts of total compensation reported for Mr. Sell (our Chief Executive Officer) for each corresponding year in the “Total” column of the Summary Compensation Table. See “Executive Compensation – Summary Compensation Table.” (2) Amounts reported in this column represent the amount of “compensation actually paid” to Mr. Sell, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Mr. Sell during the applicable year. The increases and decreases in these values are attributable largely to the changes in the value of Mr. Sell’s pre-IPO equity compensation awards in light of stock price movements. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Mr. Sell’s total compensation for each year to determine the compensation actually paid: Year 2021 2022 SCT Total Compensation $ 1,256,250 $ 5,789,157 Less, value of Stock and Option Awards reported in SCT — $ 4,500,032 Plus, Year-End value of Stock and Option Awards Granted in Fiscal Year that are Unvested and Outstanding — $ 2,812,164 Plus, Change in Fair Value (from prior year-end) of Prior Year Stock and Option Awards that are Outstanding and Unvested $57,728,000 ($27,495,000) Plus, FMV of Stock and Option Awards Granted this Year and that Vested this Year — — Plus, Change in Fair Value (from prior year-end) of Prior Year Stock and Option Awards that Vested this Year $20,903,000 ($ 7,418,000) Less Prior Year Fair Value of Prior Year Stock and Option Awards that Failed to Vest this Year — — Total Adjustments $78,631,000 ($36,600,868) Actual Compensation Paid $79,887,250 ($ 30,811,711) (3) For the portion of “compensation actually paid” that is based on year-end stock prices, $16.14 was used for 2022 and $27.00 was used for 2021. (4) Amounts reported in this column represent the average of the amounts reported for the Company’s NEOs as a group (excluding Mr. Sell) in the “Total” column of the Summary Compensation Table in each applicable year. The names of each of the NEOs (excluding Mr. Sell) included for purposes of calculating the average amounts in each applicable year are as follows: (i) for 2022, Messrs. Bensley, Shaker, Venkatachaliah and Desai and (ii) for 2021, Messrs. Bensley, Shaker, Venkatachaliah, Desai and Halkias. (5) Amounts reported in this column represent the average amount of “compensation actually paid” to the NEOs as a group (excluding Mr. Sell), as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the NEOs as a group (excluding Mr. Sell) during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to average total compensation to determine the compensation actually paid: Year 2021 2022 Average SCT Total Compensation $ 4,001,770 $1,961,158 Less, value of Stock and Option Awards reported in SCT $ 3,307,199 $1,250,024 Plus, Year-End value of Stock and Option Awards Granted in Fiscal Year that are Unvested and Outstanding $ 4,366,866 $ 781,166 Plus, Change in Fair Value (from prior year end) of Prior Year Stock and Option Awards that are Outstanding and Unvested $ 780,300 ($2,545,313) Plus, FMV of Stock and Option Awards Granted this Year and that Vested this Year — — Plus, Change in Fair Value (from prior year-end) of Prior Year Stock and Option Awards that Vested this Year $20,359,025 ($ 357,438) Less Prior Year Fair Value of Prior Year Stock and Option Awards that Failed to Vest this Year — — Total Adjustments $22,198,992 ($3,371,609) Actual Compensation Paid $26,200,762 ($1,410,451) (6) Represents the peer group TSR (S&P 500 Health Care Index) as reflected in our Annual Report on Form 10-K pursuant to item 201(e) of Regulation S-K for the fiscal year ended December 31, 2022. Each year reflects what the cumulative value of $100 would be, including reinvestment of dividends, if such amount were invested on April 14, 2021. (7) Reflects “Net Income” in the Company’s Consolidated Financial Statements included in the Company’s Annual Reports on Form 10-K for each of the years ended December 31, 2022 and 2021. (8) Company-selected measure is Adjusted EBITDA, which is a non-GAAP financial measure that is defined as net income (loss) adjusted to exclude: (i) income (loss) from discontinued operations, net of income taxes, (ii) interest expense, (iii) income tax expense (benefit), (iv) depreciation and amortization, (v) geography entry costs, (vi) stock-based compensation expense, (vii) severance and related costs, and (viii) certain other items that are not considered by us in the evaluation of ongoing operating performance. We chose Adjusted EBITDA as our Company-selected measure for evaluating pay versus performance because, among other reasons, it is a performance metric in our annual incentive plan. See “Executive Compensation – Elements of Our Executive Compensation Program – Annual Incentive Compensation.” | |
| Company Selected Measure Name | Adjusted EBITDA | |
| Named Executive Officers, Footnote [Text Block] | (4) Amounts reported in this column represent the average of the amounts reported for the Company’s NEOs as a group (excluding Mr. Sell) in the “Total” column of the Summary Compensation Table in each applicable year. The names of each of the NEOs (excluding Mr. Sell) included for purposes of calculating the average amounts in each applicable year are as follows: (i) for 2022, Messrs. Bensley, Shaker, Venkatachaliah and Desai and (ii) for 2021, Messrs. Bensley, Shaker, Venkatachaliah, Desai and Halkias. | |
| Peer Group Issuers, Footnote [Text Block] | (6) Represents the peer group TSR (S&P 500 Health Care Index) as reflected in our Annual Report on Form 10-K pursuant to item 201(e) of Regulation S-K for the fiscal year ended December 31, 2022. Each year reflects what the cumulative value of $100 would be, including reinvestment of dividends, if such amount were invested on April 14, 2021. | |
| PEO Total Compensation Amount | $ 5,789,157 | $ 1,256,250 |
| PEO Actually Paid Compensation Amount | $ (30,811,711) | 79,887,250 |
| Adjustment To PEO Compensation, Footnote [Text Block] | (2) Amounts reported in this column represent the amount of “compensation actually paid” to Mr. Sell, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Mr. Sell during the applicable year. The increases and decreases in these values are attributable largely to the changes in the value of Mr. Sell’s pre-IPO equity compensation awards in light of stock price movements. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Mr. Sell’s total compensation for each year to determine the compensation actually paid: Year 2021 2022 SCT Total Compensation $ 1,256,250 $ 5,789,157 Less, value of Stock and Option Awards reported in SCT — $ 4,500,032 Plus, Year-End value of Stock and Option Awards Granted in Fiscal Year that are Unvested and Outstanding — $ 2,812,164 Plus, Change in Fair Value (from prior year-end) of Prior Year Stock and Option Awards that are Outstanding and Unvested $57,728,000 ($27,495,000) Plus, FMV of Stock and Option Awards Granted this Year and that Vested this Year — — Plus, Change in Fair Value (from prior year-end) of Prior Year Stock and Option Awards that Vested this Year $20,903,000 ($ 7,418,000) Less Prior Year Fair Value of Prior Year Stock and Option Awards that Failed to Vest this Year — — Total Adjustments $78,631,000 ($36,600,868) Actual Compensation Paid $79,887,250 ($ 30,811,711) | |
| Non-PEO NEO Average Total Compensation Amount | $ 1,961,158 | 4,001,770 |
| Non-PEO NEO Average Compensation Actually Paid Amount | $ (1,410,451) | 26,200,762 |
| Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | (5) Amounts reported in this column represent the average amount of “compensation actually paid” to the NEOs as a group (excluding Mr. Sell), as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the NEOs as a group (excluding Mr. Sell) during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to average total compensation to determine the compensation actually paid: Year 2021 2022 Average SCT Total Compensation $ 4,001,770 $1,961,158 Less, value of Stock and Option Awards reported in SCT $ 3,307,199 $1,250,024 Plus, Year-End value of Stock and Option Awards Granted in Fiscal Year that are Unvested and Outstanding $ 4,366,866 $ 781,166 Plus, Change in Fair Value (from prior year end) of Prior Year Stock and Option Awards that are Outstanding and Unvested $ 780,300 ($2,545,313) Plus, FMV of Stock and Option Awards Granted this Year and that Vested this Year — — Plus, Change in Fair Value (from prior year-end) of Prior Year Stock and Option Awards that Vested this Year $20,359,025 ($ 357,438) Less Prior Year Fair Value of Prior Year Stock and Option Awards that Failed to Vest this Year — — Total Adjustments $22,198,992 ($3,371,609) Actual Compensation Paid $26,200,762 ($1,410,451) | |
| Total Shareholder Return Amount | $ 70.17 | 117.39 |
| Peer Group Total Shareholder Return Amount | 118 | 120.35 |
| Net Income (Loss) | $ (106,864,000) | $ (406,787,000) |
| Company Selected Measure Amount | 4,251,000 | (38,619,000) |
| PEO Name | Mr. Sell | Mr. Sell |
| Share price | $ 27 | $ 16.14 |
| Measure [Axis]: 1 | ||
| Pay vs Performance Disclosure [Table] | ||
| Non-GAAP Measure Description [Text Block] | (8) Company-selected measure is Adjusted EBITDA, which is a non-GAAP financial measure that is defined as net income (loss) adjusted to exclude: (i) income (loss) from discontinued operations, net of income taxes, (ii) interest expense, (iii) income tax expense (benefit), (iv) depreciation and amortization, (v) geography entry costs, (vi) stock-based compensation expense, (vii) severance and related costs, and (viii) certain other items that are not considered by us in the evaluation of ongoing operating performance. We chose Adjusted EBITDA as our Company-selected measure for evaluating pay versus performance because, among other reasons, it is a performance metric in our annual incentive plan. See “Executive Compensation – Elements of Our Executive Compensation Program – Annual Incentive Compensation.” | |
| PEO [Member] | Total Adjustments [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | $ (36,600,868) | $ 78,631,000 |
| PEO [Member] | Value of Stock and Option Awards Reported in SCT [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | (4,500,032) | 0 |
| PEO [Member] | Year-End value of Stock and Option Awards Granted in Fiscal Year that are Unvested and Outstanding [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | 2,812,164 | 0 |
| PEO [Member] | Change in Fair Value (from prior year-end) of Prior Year Stock and Option Awards that are Outstanding and Unvested [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | (27,495,000) | 57,728,000 |
| PEO [Member] | FMV of Stock and Option Awards Granted this Year and that Vested this Year [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | 0 | 0 |
| PEO [Member] | Change in Fair Value (from prior year-end) of Prior Year Stock and Option Awards that Vested this Year [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | (7,418,000) | 20,903,000 |
| PEO [Member] | Prior Year Fair Value of Prior Year Stock and Option Awards that Failed to Vest this Year [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | 0 | 0 |
| Non-PEO NEO [Member] | Total Adjustments [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | (3,371,609) | 22,198,992 |
| Non-PEO NEO [Member] | Value of Stock and Option Awards Reported in SCT [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | (1,250,024) | (3,307,199) |
| Non-PEO NEO [Member] | Year-End value of Stock and Option Awards Granted in Fiscal Year that are Unvested and Outstanding [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | 781,166 | 4,366,866 |
| Non-PEO NEO [Member] | Change in Fair Value (from prior year-end) of Prior Year Stock and Option Awards that are Outstanding and Unvested [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | (2,545,313) | 780,300 |
| Non-PEO NEO [Member] | FMV of Stock and Option Awards Granted this Year and that Vested this Year [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | 0 | 0 |
| Non-PEO NEO [Member] | Change in Fair Value (from prior year-end) of Prior Year Stock and Option Awards that Vested this Year [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | (357,438) | 20,359,025 |
| Non-PEO NEO [Member] | Prior Year Fair Value of Prior Year Stock and Option Awards that Failed to Vest this Year [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | $ 0 | $ 0 |
